Government Support of Meaningful Drug and Device Innovation: Pathways and Challenges

The US government is a central driver of transformative drug and device innovation through NIH funding and early‑stage research, but too often ends up paying high prices for products that offer little added clinical benefit. It contends that Congress should strengthen policies that link payment and coverage to meaningful evidence of benefit, while expanding public investment in high‑value innovation, to protect patients and taxpayers from low‑value, high‑cost therapies.